Wilmington, United States
Incyte, founded in 1991, is a global leader in the biopharmaceutical landscape, known for its commitment to resolving unmet medical needs through innovative drug discovery and development in the fields of oncology and inflammation & autoimmunity. With its headquarters in Wilmington, Delaware, the company operates with a workforce exceeding 2,600 across North America, Europe, and Asia.
Endowed with specialized expertise in medicinal chemistry and biology, Incyte boasts a robust portfolio of first-in-class medicines and a diversified pipeline of therapies. Importantly, the majority of these clinical candidates are the product of internal innovation. The company has been recognized by Science magazine and Newsweek for its strong workplace culture and impact.
Their latest funding, a $44.30M Post IPO Equity investment from Scuti Capital Management in March 2023, underscores confidence in their ongoing potential. Given their profound impact and strategic focus, Incyte remains an attractive prospect for investors seeking substantial contributions to healthcare advancements.
Incyte Diagnostics